Literature DB >> 10689362

Development of pharmacological agents for targeting neurotrophins and their receptors.

H U Saragovi1, K Gehring.   

Abstract

Neurotrophins comprise a family of protein growth factors that control the survival, growth, and/or differentiation of neurons and several other cell populations derived from the neuroectoderm. Neurotrophins and their receptors are important targets for the therapy of human disease, with potential applications ranging from the treatment of chronic or acute neurodegeneration to pain and cancer. Neurotrophins have been used clinically but are poor pharmacological agents. Consequently, approaches to develop pharmacological agents that target neurotrophins, their receptors or neurotrophin signaling pathways have been attempted.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10689362     DOI: 10.1016/s0165-6147(99)01444-3

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  22 in total

1.  Transmembrane helix predictions revisited.

Authors:  Chien Peter Chen; Andrew Kernytsky; Burkhard Rost
Journal:  Protein Sci       Date:  2002-12       Impact factor: 6.725

2.  Aerobic exercise alters analgesia and neurotrophin-3 synthesis in an animal model of chronic widespread pain.

Authors:  Neena K Sharma; Janelle M Ryals; Byron J Gajewski; Douglas E Wright
Journal:  Phys Ther       Date:  2010-03-25

3.  Molecular simulation of the binding of nerve growth factor peptide mimics to the receptor tyrosine kinase A.

Authors:  Marco Berrera; Antonino Cattaneo; Paolo Carloni
Journal:  Biophys J       Date:  2006-06-23       Impact factor: 4.033

Review 4.  Cardiovascular actions of neurotrophins.

Authors:  Andrea Caporali; Costanza Emanueli
Journal:  Physiol Rev       Date:  2009-01       Impact factor: 37.312

Review 5.  Neuroprotective strategies in Alzheimer's disease.

Authors:  Frank M Longo; Stephen M Massa
Journal:  NeuroRx       Date:  2004-01

Review 6.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 7.  Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.

Authors:  Robert D Wyse; Gary L Dunbar; Julien Rossignol
Journal:  Int J Mol Sci       Date:  2014-01-23       Impact factor: 5.923

8.  C6 Glioma-Secreted NGF and FGF2 Regulate Neuronal APP Processing Through Up-Regulation of ADAM10 and Down-Regulation of BACE1, Respectively.

Authors:  Huiping Xie; Zhimin Xiao; Jian Huang
Journal:  J Mol Neurosci       Date:  2015-11-27       Impact factor: 3.444

9.  A peptidomimetic of NT-3 acts as a TrkC antagonist.

Authors:  Fouad Brahimi; Andrey Malakhov; Hong Boon Lee; Mookda Pattarawarapan; Lubijca Ivanisevic; Kevin Burgess; H Uri Saragovi
Journal:  Peptides       Date:  2009-07-30       Impact factor: 3.750

10.  Bivalent peptidomimetic ligands of TrkC are biased agonists and selectively induce neuritogenesis or potentiate neurotrophin-3 trophic signals.

Authors:  Dianjun Chen; Fouad Brahimi; Yu Angell; Yu-Chin Li; Jennifer Moscowicz; H Uri Saragovi; Kevin Burgess
Journal:  ACS Chem Biol       Date:  2009-09-18       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.